surmount-1 tirzepatide non-diabetic obesity trial For the first time, and semaglutide were put in the same trial. SURMOUNT-5. Phase 3b RCT. 751 adults with obesity, no diabetes. 72 weeks. Both drugs at maximum tolerated dose. The SURMOUNT-1

A customized, patient-centric approach Compounded tirzepatide with vitamin B6 is a personalized version of the medication made according to the patients individual needs

This produces appetite suppression (via hypothalamic signaling), delayed gastric emptying, glucose-dependent insulin secretion, and glucagon suppression

Today, safer alternatives like methocarbamol, baclofen, and non-medication approaches are increasingly preferred for managing muscle pain, keeping patient safety the main priority

This makes the program more convenient, but it also means fewer safety checkpoints compared to more hands-on clinics

Focus on showing up to train and eating enough protein

Bleeding-related events as adjacent gynaecological signals Although bleeding is not a vaginal mucosal endpoint, it is clinically adjacent because patients may describe spotting as vaginal bleeding and present alongside discharge/pain